stab for R -
A Data Analysis Tool for
Drug Stability with R (demo)
Created by Hsin-ya Lee (hsinyalee@gmail.com)
Yung-jin Lee (mobilePK@gmail.com)
Introduction:
This package is used to analyze stability data. We follow the ICH
guideline 'Q1E Evaluation for Stability Data' (linked from USA FDA site) to design this tool (Here's its .pdf.). This guideline describes when extrapolation
should be
considered as proposing a retest period for a drug substance or a shelf life
of a drug product that extends beyond the period covered by available data from
the stability study under the long-term storage condition.
Methods:
This package includes
two steps. In the first step, Decision Tree for Data Evaluation
follows "Appendix A" of ICH guideline "Q1E
Evaluation for Stability Data" that assists users evaluating stability data and
guide users to consider doing an extrapolation for a
proposed retest period or shelf life.
In the second
step, Statistical Approaches to Stability Data Analysis is
conducted for two different situations. First one is for a single batch.
This approach estimates the retest period or shelf life for a
single batch of drug product. The relationship between residuals and time is assumed to be
linear. Two-sided 95 % confidence intervals of the regression line for
residuals (% relative to the original amount) of a drug product intersect with upper and lower acceptance
criteria of label claimed. Then, the shortest one is the shelf life.
When there are multiple batches (e.g. 3 batched) available, analysis of
covariance (ANCOVA) is first employed to test the difference in slopes and
intercepts of the regression lines with different factors
(packages, dosage forms, etc.). Then, based on the
statistical results, there can be three possibilities.
(1). slope
(P>=0.25) and intercept (P>=0.25): the tests for
equality of slopes and equality of intercepts are all no differences. The data from all batches then
should be
combined. Then, a single retest period or shelf life is estimated
from the combined data. (2). slope
(P>=0.25) and intercept (P<0.25): the test rejects
the hypothesis of equality of intercepts but fails to reject the
hypothesis with that all
slopes are equal. The data should be
combined to estimate the common slope. The retest
periods or shelf lives for individual batches can be estimated. Then,
the shortest estimate among batches should be chosen as the shelf life
for all batches. (3). [slope
(P<0.25) and intercept (P>=0.25)] or [slope (P<0.25) and intercept
(P<0.25)]: the result in this scenario shows that the test rejects the hypothesis of
equality of all slopes. It is not appropriate to combine the data from all
batches in this situation. The retest periods or shelf lives for individual batches
is estimated. Then, the shortest estimate among batches should be
chosen as the shelf life for all batches.
Please note the "batch" should be entered only as the numeric (1, 2, 3...)
format; otherwise, it will cause error.
Cross Validation with FDA provided SAS Stability
programs: Please check with
this .pdf file and use bookmarks to browse
this pdf file. Please note that in SAS output, the lines for
the upper and lower ranges were drawn between 90% and 110% (set as default). We did not change that
with its SAS code (should be the one called stabgraf.sas), though we used different ranges; however, they would not affect the final results. They were just like marks over there.
